Genetic markers in oligodendroglial tumours
- PMID: 22933885
- PMCID: PMC3423675
- DOI: 10.2478/v10019-010-0007-y
Genetic markers in oligodendroglial tumours
Abstract
Background: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5-20% of all gliomas.
Conclusions: Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice.
Keywords: chemotherapy; genetic markers; oligodendroglioma; prognosis.
References
-
- Gilbert MR, Lang FF. Management of patients with low-grade gliomas. Neurol Clin. 2007;25:1073–88. - PubMed
-
- Strojnik T, Gornik-Kramberger K. [Stereotactic biopsy of brain tumours – Maribor experience with MHT stereotaxy system]. [Slovenian] Zdrav Vestn. 2008;77:601–8.
-
- Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME. Advances in brain tumor surgery. Neurol Clin. 2007;25:975–1003. - PubMed
-
- Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol. 2003;60:443–56. - PubMed
-
- Strojnik A. Search of the shortest regimen: fractionation of a fully isoeffective combination of hyperfractionated and hypofractionated treatment. Radiol Oncol. 2008;42:170–2.
LinkOut - more resources
Full Text Sources